Subtopic Deep Dive
BRCA1 BRCA2 Mutations Ovarian Cancer
Research Guide
What is BRCA1 BRCA2 Mutations Ovarian Cancer?
BRCA1 and BRCA2 germline mutations are pathogenic variants conferring high lifetime risk of ovarian cancer, with prevalence of 10-15% in unselected cases and guiding precision prevention via genetic screening and risk-reducing salpingo-oophorectomy.
Population studies estimate BRCA1/2 penetrance at 39-44% for ovarian cancer by age 70 (Kuchenbaecker et al., 2017, 2687 citations). Germline mutations occur in 13-17% of ovarian cancer patients (Risch et al., 2001, 987 citations; Alsop et al., 2012, 1144 citations). Over 10 key papers from 1998-2021 detail risks, prevalence, and interventions.
Why It Matters
BRCA1/2 testing identifies carriers for risk-reducing salpingo-oophorectomy (RRSO), reducing ovarian cancer risk by 80-96% (Kauff et al., 2002, 1244 citations; Rebbeck et al., 2009, 915 citations). Mutation carriers show superior response to platinum-based chemotherapy (Alsop et al., 2012). NCCN guidelines recommend cascade testing based on prevalence data (Daly et al., 2021, 1069 citations), enabling family-wide prevention.
Key Research Challenges
Heterogeneous Penetrance Estimates
BRCA1/2 lifetime ovarian cancer risks vary across studies due to founder effects and modifiers (Ford et al., 1998, 3033 citations). Prospective cohorts refine estimates but require large sample sizes (Kuchenbaecker et al., 2017). Population stratification confounds prevalence calculations (Risch et al., 2001).
Beyond BRCA1/2 Mutations
12 additional genes contribute to hereditary ovarian cancer, complicating screening panels (Walsh et al., 2011, 928 citations). Integrated genomic analyses reveal co-occurring aberrations (Bell et al., 2011, 7936 citations). Multi-gene testing alters risk assessment protocols.
RRSO Timing Optimization
Balancing ovarian preservation against cancer risk demands age-specific guidelines (Kauff et al., 2002). Meta-analyses quantify reductions but highlight residual fallopian tube risks (Rebbeck et al., 2009). Long-term endocrine effects require monitoring.
Essential Papers
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Michael J. Birrer et al. · 2011 · Nature · 7.9K citations
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients' lives. The Cancer Genome Atlas project has analysed mes...
Ovarian cancer statistics, 2018
Lindsey A. Torre, Britton Trabert, Carol DeSantis et al. · 2018 · CA A Cancer Journal for Clinicians · 3.6K citations
Abstract In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an ove...
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Deborah Ford, Douglas F. Easton, Michael R. Stratton et al. · 1998 · The American Journal of Human Genetics · 3.0K citations
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · 2017 · JAMA · 2.7K citations
These findings provide estimates of cancer risk based on BRCA1 and BRCA2 mutation carrier status using prospective data collection and demonstrate the potential importance of family history and mut...
Risk-Reducing Salpingo-oophorectomy in Women with a<i>BRCA1</i>or<i>BRCA2</i>Mutation
Noah D. Kauff, Jaya M. Satagopan, Mark E. Robson et al. · 2002 · New England Journal of Medicine · 1.2K citations
Salpingo-oophorectomy in carriers of BRCA mutations can decrease the risk of breast cancer and BRCA-related gynecologic cancer.
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop, Sián Fereday, Cliff Meldrum et al. · 2012 · Journal of Clinical Oncology · 1.1K citations
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line mutation on response requires further inve...
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Mary B. Daly, Tuya Pal, Michael P. Berry et al. · 2021 · Journal of the National Comprehensive Cancer Network · 1.1K citations
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased ri...
Reading Guide
Foundational Papers
Start with Bell et al. (2011, 7936 citations) for genomic context, Ford et al. (1998) for penetrance methods, Kauff et al. (2002) for RRSO evidence.
Recent Advances
Kuchenbaecker et al. (2017) for prospective risks; Daly et al. (2021) for clinical guidelines; Walsh et al. (2011) for multi-gene expansion.
Core Methods
Germline sequencing, massively parallel sequencing (Walsh 2011), prospective cohort penetrance (Kuchenbaecker 2017), meta-analysis of RRSO (Rebbeck 2009).
How PapersFlow Helps You Research BRCA1 BRCA2 Mutations Ovarian Cancer
Discover & Search
Research Agent uses citationGraph on Kuchenbaecker et al. (2017) to map 50+ connected papers on BRCA penetrance, then exaSearch for 'BRCA2 ovarian cancer prevalence post-2020' to find updates beyond provided lists.
Analyze & Verify
Analysis Agent runs readPaperContent on Alsop et al. (2012) to extract mutation frequencies, verifies response with CoVe against Risch et al. (2001), and uses runPythonAnalysis for statistical comparison of response rates via pandas survival analysis with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in RRSO timing across Kauff et al. (2002) and Rebbeck et al. (2009), flags contradictions in penetrance; Writing Agent applies latexSyncCitations and latexCompile to generate a review section with exportMermaid for risk reduction flowcharts.
Use Cases
"Meta-analyze BRCA1/2 prevalence across population studies"
Research Agent → searchPapers('BRCA ovarian cancer prevalence') → Analysis Agent → runPythonAnalysis(pandas meta-analysis of Risch 2001 + Alsop 2012 frequencies) → forest plot CSV.
"Draft NCCN-style RRSO guideline table"
Synthesis Agent → gap detection (Kauff 2002 vs Daly 2021) → Writing Agent → latexEditText + latexSyncCitations → latexCompile → PDF guideline table.
"Find genomic analysis code for TCGA ovarian data"
Research Agent → citationGraph(Bell 2011) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → BRCA mutation workflow scripts.
Automated Workflows
Deep Research workflow synthesizes 50+ papers via searchPapers → citationGraph → DeepScan (7-step verification with CoVe checkpoints on penetrance claims from Kuchenbaecker 2017). Theorizer generates hypotheses on modifier genes by analyzing gaps between Walsh 2011 multi-gene findings and BRCA-focused studies. DeepScan applies runPythonAnalysis to compare RRSO efficacy meta-data from Rebbeck 2009.
Frequently Asked Questions
What is the ovarian cancer penetrance for BRCA1/2 carriers?
Prospective data estimate 39-44% lifetime risk by age 70, varying by mutation location (Kuchenbaecker et al., 2017).
What methods quantify BRCA mutation prevalence?
Population series test unselected ovarian cancer cases; germline sequencing finds 13-17% prevalence (Risch et al., 2001; Alsop et al., 2012).
Which are key papers on BRCA ovarian cancer?
Foundational: Bell et al. (2011, 7936 citations, TCGA genomics); Kauff et al. (2002, RRSO); recent: Daly et al. (2021, NCCN guidelines).
What open problems exist in BRCA ovarian research?
Optimizing RRSO timing, identifying modifiers of penetrance, and incorporating 12+ other hereditary genes into screening (Walsh et al., 2011).
Research Ovarian cancer diagnosis and treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching BRCA1 BRCA2 Mutations Ovarian Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.